U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07398963) titled 'Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma' on Feb. 03.
Brief Summary: To study the safety and effectiveness of oncolytic Vaccinia VIrus-Delivered Targeted CD19 In Vivo CAR-T/M Therapy for Refractory/Relapsed B-Cell Lymphoma
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Refractory/Relapsed B-cell Lymphoma
Intervention:
BIOLOGICAL: CD19-CAR novel oncolytic vaccinia virus
Injection of CD19-CAR novel oncolytic vaccinia virus which carrying the CD19-CAR gene (RGV005) is designed to locally induce the in situ generation of...